Phase 3 ATLAS trial in 180 patients with multiple myeloma after autologous HSCT: carfilzomib-lenalidomide-dexamethasone versus lenalidomide gave 4-year PFS of 67.5% vs 38.0% (HR 0.46); serious adverse events were 30% vs 23%.
RCTn = 180
Dytfeld et al. Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial